Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine
Brief Summary: The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another atypical antipsychotic, olanzapine. In the second phase of this study, investigators will assess the effectiveness of behavioral therapy in reducing body weight in risperdone-treated patients who are overweight or have problems with diabetes or blood sugar.


Options:
A: Inclusion Criteria:

* You must be 18 to 60 years old
* You must have been diagnosed with schizophrenia or schizoaffective disorder
* You must be able to visit the doctor's office 8 times over a 9 week period
* You must agree to participate with all tests and examinations that are required for this study

Exclusion Criteria:

* You are a woman and are pregnant or breastfeeding
* You presently have an acute or unstable medical illness
* You have a history of an allergic reaction to olanzapine
* You are taking medications that are not permitted in this study. Your physician will discuss these with you
* You have taken part in another clinical research trial within the last 30 days or you have received treatment with a drug in the last 30 days that has not received regulatory approval.
B: Inclusion Criteria:

* Patients with schizophrenia treated with clozapine (200-900 mg/day), who gained at least 2.5 kg while on clozapine.

Exclusion Criteria:

* Patients known to be allergic to aripiprazole
* Hospitalized patients
* Patients who have previously received study medication in an aripiprazole clinical study or who have participated in any clinical trial with an investigational agent within the past month.
C: Inclusion Criteria:

* Patients diagnosed as schizophrenia by DSM-IV-TR criteria both in inpatients
* Patients who are symptomatically stable, as judged by the treating psychiatrist, and receive a stable dose of risperidone for a minimum of 2 weeks before enrollment.
* Patients with ability to complete various questionnaires.
* Patients and/or their legal guardians/representatives who sufficiently understand the objective of the study and sign informed consent form

Exclusion Criteria:

* Active psychotic symptoms, including severe behavioral disturbance
* Relevant history of or current presence of any significant or unstable medical disease
* A woman who is pregnant, breast-feeding or planning to become pregnant during the study period
* Patients with the history of serious allergy or multiple adverse drug reactions
* Patients with the history of taking paliperidone ER within 60 days
* Patients with history of taking clozapine within 60 days
* Patients who require the treatment of other medications influencing CNS, except permitted concomitant drugs in advance
D: Inclusion Criteria:

* Patients who have a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) diagnosis of schizophrenia or schizoaffective disorder
* Taking a stable dose of olanzapine for at least 30 days
* Have not experienced an acute exacerbation of their psychotic symptoms in the preceding 3 months
* Either had only a marginal clinical response to olanzapine, or had unacceptable side effects related to weight gain including obesity, diabetes or abnormal glucose metabolism

Exclusion Criteria:

* Patients with a history of treatment failure with, or significant adverse events attributable to, risperidone, or known sensitivity to risperidone
* A history of antipsychotic therapy other than olanzapine in the 30 days preceding randomization
* Presence of serious or unstable illnesses: liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric or metabolic disturbances
* Diagnosis of substance dependence
* Pregnant or nursing female, or those lacking adequate contraception

Answer: D